1. 658PPatient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA). (23rd October 2018) Authors: Morlock, R; Krukas-Hampel, M R; Türeci, Ö Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 807PProlonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study. (23rd October 2018) Authors: Tombal, B; Hussain, M; Penson, D; Attard, G; Sternberg, C N; Phung, D; Morlock, R; Modelska, K; Ramaswamy, K; Ivanescu, C; Saad, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0456 Rate of hospitalization for heart failure is lower in patients with controlled gout versus uncontrolled gout. (15th June 2017) Authors: Morlock, R; Chevalier, P; Klein, AB Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0728 Osteoarthritis and gout: real-world evidence evaluating patient characteristics, treatment patterns, and healthcare utilization. (15th June 2017) Authors: Samuels, S Krasnokutsky; Pillinger, M; Kabadi, S; Taylor, DC; Morlock, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 766 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 853PARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups. (1st October 2019) Authors: Stenzl, A; Szmulewitz, R Z; Petrylak, D P; Holzbeierlein, J; Villers, A; Azad, A A; Alcaraz, A; Alekseev, B Y; Iguchi, T; Shore, N D; Rosbrook, B; Baron, B; Haas, G P; Morlock, R; Ramaswamy, K; Armstrong, A J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FRI0720 Characteristics of patients with gout treated to sua target that continue to experience flares: data from france, germany, italy, spain, uk and us. (15th June 2017) Authors: Morlock, R; Taylor, DC; Baumgartner, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 763 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0457 Less than half of patients treated with high-dose allopurinol reach sua target. (15th June 2017) Authors: Morlock, R; Taylor, DC; Baumgartner, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗